AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca 
Welcome,         Profile    Billing    Logout  
 1 Disease   6 Trials   6 Trials   1075 News 


12345678910111213...1314»
  • ||||||||||  Xarelto (rivaroxaban) / J&J
    Time is Brain: Apixaban and Rivaroxaban Reversal Strategies for Intracerebral Hemorrhage Requiring Surgery (Harbor Ballrooms D-I) -  Oct 17, 2024 - Abstract #NCS2024NCS_513;    
    Throughout the session, an interactive case will engage the audience to apply the knowledge they are learning to real life situations that may occur in the hospital setting. Due to the substantial increase in DOAC use in the community, hospitals are seeing an increasing number of patients who present to the ED and ICU setting with an intracerebral hemorrhage on rivaroxaban or apixaban prompting the need for quick, safe, and effective reversal strategies.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Reprint of: Four-factor prothrombin complex concentrate versus andexanet (Pubmed Central) -  Oct 3, 2024   
    Combining heparin and AT supplementation provided more effective than heparin alone in mitigating GDXa-induced heparin resistance by compensating for the loss of TFPI. There were no significant differences in hemostatic efficacy, in-hospital mortality, and number of thrombotic events between 4F-PCC and AA.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Review, Journal:  Major Publications in the Critical Care Pharmacotherapy Literature: 2023. (Pubmed Central) -  Oct 3, 2024   
    There were no significant differences in hemostatic efficacy, in-hospital mortality, and number of thrombotic events between 4F-PCC and AA. This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal, Surgery:  Impact of elevated direct factor Xa inhibitor plasma levels on perioperative blood loss in patients undergoing urgent surgery. (Pubmed Central) -  Sep 25, 2024   
    Despite markedly elevated plasma concentrations of residual direct FXa inhibitors, perioperative RBC loss was limited in patients undergoing urgent noncardiac surgery. The intraoperative watch-and-wait strategy with selective intraoperative FXa inhibitor reversal or treatment only when required appears to be an appropriate approach.
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Clinical guideline, Journal:  Reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH: R1. (Pubmed Central) -  Sep 21, 2024   
    In-hospital mortality occurred in 2 of 7 patients with 1 additional patient discharged to hospice care. Andexanet
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa. (Pubmed Central) -  Aug 20, 2024   
    This study highlights challenges in ordering and administering AA at our institution and brings awareness to potential similar concerns at other institutions. These challenges also identified the need for optimized order sets, a streamlined administration process, and frequent provider education to improve patient safety.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, Savaysa (edoxaban) / Daiichi Sankyo, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Prognosis and Characteristics of In-Hospital Major Bleeding Patients Taking Factor-Xa Inhibitors in Japan: REAL-J-Bleeding Study (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2971;    
    The distribution of bleeding sites was as follows: upper gastrointestinal bleeding, 30.3%; intracranial hemorrhage, 16.0%; lower gastrointestinal bleeding, 11.7%; trauma-related bleeding, 9.1%; and other sites, 38.2%. During the hospitalization (median length of stay 11.0 days, range 1-911 days), the proportion of patients who experienced thromboembolic events and in-hospital death were 0.5% (95%CI: 0.3% to 0.7%) and 7.1% (95%CI: 6.6% to 7.7%), respectively.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    AIM65 as an Indicator of Rebleed and Mortality Risk in Patients Using Factor Xa Inhibitors Hospitalized for a Gastrointestinal (GI) Bleed (Late-Breaking Abstract) (Terrace Ballroom 1) -  Aug 20, 2024 - Abstract #ACG2024ACG_488;    
    We conducted a retrospective study of US adults hospitalized for factor Xa inhibitor-associated GI bleeding treated with andexanet alfa (AA) or 4-factor prothrombin complex concentrate (4F-PCC) AC reversal...Patients must have received apixaban or rivaroxaban before admission for GI bleeding... In patients undergoing factor Xa inhibitor reversal for GI bleeding, the AIM65 score was useful for identifying patients with a high likelihood of mortality and rebleeding, particularly for scores > 3.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Fatal drug reaction to andexanet alfa: a case report. (Pubmed Central) -  Aug 19, 2024   
    Although infusion site reactions have been reported and are relatively common, this is to date the first case of a fatal drug reaction andexanet alfa. This knowledge can be factored into physicians' risk-benefit decisions when treating patients with oral anti-FXa anticoagulant-associated major haemorrhage.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Review, Journal:  Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review. (Pubmed Central) -  Aug 12, 2024   
    When patients who are taking a DOAC require an elective surgical or nonsurgical procedure, standardized management protocols can be applied that do not require testing DOAC levels or heparin bridging. When patients taking a DOAC require an emergent, urgent, or semiurgent surgical procedure, anticoagulant reversal agents may be appropriate when DOAC levels are elevated or not available.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Review of Concomitant Andexanet Alfa and Prothrombin Complex Concentrate in Intracranial Hemorrhage (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_5328;    
    The care team discussed the option of administering andexanet alfa for further hemorrhage control, but a decision was made to withhold it unless the patient would undergo surgery. This case report will review the literature on the concomitant use of andexanet alfa and prothrombin complex concentrate.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
     (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_3879;    
    Care was subsequently withdrawn. This highlights the complexity of anticoagulant therapy, massive coagulopathy and its treatment.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world:  Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya (clinicaltrials.gov) -  Jul 17, 2024   
    P=N/A,  N=100, Recruiting, 
    Of 5101 AUGIB cases enrolled, 31%(1566) were on anticoagulants Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Andexanet Alfa for Edoxaban Reversal and Associated Thromboelastography Changes in Surgical Pulmonary Embolectomy. (Pubmed Central) -  Jul 15, 2024   
    This is the first report of a change in TEG findings before and after administration of andexanet alfa in a cardiac surgery patient taking factor Xa inhibitor. Monitoring CK-R in TEG may help evaluate the anticoagulant effect of factor Xa inhibitors and the reversal effect of andexanet alfa.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Reply to "Letter to Dobesh et (Pubmed Central) -  Jul 12, 2024   
    No abstract available No abstract available
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Review, Journal:  Overdosing of direct oral anticoagulants (Pubmed Central) -  Jun 25, 2024   
    In the analysis of the controlled studies alone, Andexanet alpha is associated with an increased risk of thromboembolic events. The sensitization of clinicians is important to ensure a
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Rapid detection of FXa inhibitor activity using point of care testing (Plenary Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1952;    
    The anti-Xa levels were compared to the clotting time (CT) on RVV-test and there was a significant and positive correlation between the anti-Xa activity and CT. The Pearson correlation coefficient was 0.86 for apixaban, 0.84 for rivaroxaban and 0.84 for enoxaparin.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Management of patients requiring oral anticoagulant reversal for surgical emergencies or major bleeding: clinical practice in the United States (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1618;    
    PCCs were the most selected treatment for VKA reversal for emergency surgery (43.7%) and bleeding (48.9%) of which 38.8% and 41.7% were 4F-PCCs, Recombinant FVIIa (rFVIIa) use was 1.7%, and 3.8%, and FFP 26.8% and 31.4%.(Figure 1) For DOAC-reversal, PCCs were the most selected reversal agent for emergency surgery (65.9%) and major bleeding (62.5%), including 4F-PCCs, 3F-PCCs, and activated PCCs (Figure 2). rFVIIa was used in 5.8% and 9.5%, and FFP was in 24-25% of respondents for bleeding or surgery.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Assessing andexanet alfa Prescribing and Administration Practices: A Single Institution Study to Improve Patient Safety (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1551;    
    Eight (36%) dosing sets met our ordering benchmarks regarding appropriate dose, time since last DOAC, urgency of administration and documentation. Two (9%) dosing sets met the administrative benchmarks of being started within 30 minutes of the initial order and 13 (59%) dosing sets had timely infusion of the infusion dose after the loading dose.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Fast screening of direct oral factor Xa inhibitors, interferences in anti-Xa assays (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_783;    
    However the degree of interference strongly depends on the concentration of the interfering substance and the reagent used (Table 1). Nevertheless, heparine interference at any tested concentration in the rivaroxaban anti-Xa protocol, leads to false positive results.